Insider trading

Period: 120 months Stock: ALNY Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

131 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

131 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

131 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

131 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
131 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
131 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

131 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
2 Oct 2026
SUPRAN BRYAN EVP, CLO and Secretary
Sold at will
$398.86K 1,758 at 226.88
12.1%
Not planned
6 Apr 2026
McLaughlin Melissa Chief Human Resources Officer
Sold on a plan 5×
$755.33K 2,286 at 330.42
19.5%
Planned (10b5-1)
2 Apr 2026
McLaughlin Melissa Chief Human Resources Officer
Sold on a plan 9×
$519.01K 1,624 at 319.59
12.2%
Planned (10b5-1)
5 Mar 2026
Garg Pushkal EVP Chief R&D
Sold on a plan 4×
$778.81K 2,404 at 323.96
11.4%
Planned (10b5-1)
5 Mar 2026
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 4×
$213.18K 658 at 323.98
3.1%
Planned (10b5-1)
4 Mar 2026
Garg Pushkal EVP Chief R&D
Sold on a plan 8×
$745.98K 2,309 at 323.08
9.9%
Planned (10b5-1)
4 Mar 2026
Tanguler Tolga EVP, Chief Commercial Officer
Sold at will 8×
$745.98K 2,309 at 323.08
6.3%
Not planned
4 Mar 2026
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 8×
$204.51K 633 at 323.08
2.9%
Planned (10b5-1)
3 Mar 2026
Garg Pushkal EVP Chief R&D
Sold on a plan 4×
$567.55K 1,775 at 319.74
7.0%
Planned (10b5-1)
3 Mar 2026
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 4×
$528.19K 1,652 at 319.73
7.0%
Planned (10b5-1)
2 Mar 2026
Garg Pushkal EVP Chief R&D
Sold on a plan 10×
$562.59K 1,717 at 327.66
6.4%
Planned (10b5-1)
2 Mar 2026
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 10×
$523.58K 1,598 at 327.65
6.4%
Planned (10b5-1)
2 Mar 2026
Tanguler Tolga EVP, Chief Commercial Officer
Sold at will 10×
$523.58K 1,598 at 327.65
4.2%
Not planned
27 Feb 2026
Garg Pushkal EVP Chief R&D
Sold on a plan 5×
$1.53M 4,627 at 331.34
17.3%
Planned (10b5-1)
17 Feb 2026
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan
$677.53K 2,041 at 331.96
8.8%
Planned (10b5-1)
13 Feb 2026
Garg Pushkal EVP Chief R&D
Sold at will
$695.20K 2,242 at 310.08
8.3%
Not planned
13 Feb 2026
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan
$607.45K 1,959 at 310.08
7.8%
Planned (10b5-1)
13 Feb 2026
Tanguler Tolga EVP, Chief Commercial Officer
Sold at will
$607.45K 1,959 at 310.08
5.8%
Not planned
13 Jan 2026
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 6×
$848.06K 2,290 at 370.33
9.7%
Planned (10b5-1)
12 Jan 2026
Garg Pushkal EVP Chief R&D
Sold at will 21×
$547.93K 1,510 at 362.87
6.3%
Not planned
12 Jan 2026
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 21×
$547.93K 1,510 at 362.87
6.0%
Planned (10b5-1)
12 Jan 2026
Tanguler Tolga EVP, Chief Commercial Officer
Sold at will 21×
$547.93K 1,510 at 362.87
4.8%
Not planned
17 Nov 2025
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 11×
$5.48M 12,128 at 452.18
36.3%
Planned (10b5-1)
3 Oct 2025
Garg Pushkal EVP Chief R&D
Sold on a plan 5×
$1.36M 3,022 at 451.48
13.0%
Planned (10b5-1)
2 Oct 2025
Garg Pushkal EVP Chief R&D
Sold on a plan 12×
$1.33M 2,937 at 452.05
11.2%
Planned (10b5-1)
2 Oct 2025
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold at will 12×
$1.10M 2,441 at 452.05
8.8%
Not planned
2 Oct 2025
Tanguler Tolga EVP, Chief Commercial Officer
Sold at will 12×
$635.13K 1,405 at 452.05
4.9%
Not planned
29 Aug 2025
Tanguler Tolga EVP, Chief Commercial Officer
Sold on a plan 6×
$1.56M 3,474 at 448.37
11.8%
Planned (10b5-1)
19 Aug 2025
Garg Pushkal EVP Chief R&D
Sold on a plan 6×
$666.99K 1,455 at 458.41
6.7%
Planned (10b5-1)
18 Aug 2025
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold at will 8×
$632.76K 1,396 at 453.27
5.8%
Not planned
18 Aug 2025
Tanguler Tolga EVP, Chief Commercial Officer
Sold at will 8×
$632.76K 1,396 at 453.27
4.5%
Not planned
18 Aug 2025
Garg Pushkal EVP Chief R&D
Sold on a plan 8×
$632.76K 1,396 at 453.27
6.1%
Planned (10b5-1)
24 Mar 2025
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold on a plan
$1.63M 5,445 at 300.00
21.2%
Planned (10b5-1)
21 Mar 2025
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold on a plan
$1.23M 4,321 at 285.00
17.6%
Planned (10b5-1)
4 Mar 2025
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 4×
$203.53K 844 at 241.15
5.9%
Planned (10b5-1)
4 Mar 2025
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold on a plan 4×
$194.77K 808 at 241.05
3.2%
Planned (10b5-1)
3 Mar 2025
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 10×
$465.77K 1,911 at 243.73
11.8%
Planned (10b5-1)
3 Mar 2025
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold on a plan 10×
$426.38K 1,749 at 243.79
6.5%
Planned (10b5-1)
3 Mar 2025
Tanguler Tolga EVP, Chief Commercial Officer
Sold at will 6×
$114.82K 471 at 243.78
1.7%
Not planned
28 Feb 2025
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold at will 8×
$225.98K 935 at 241.69
6.7%
Not planned
28 Feb 2025
Tanguler Tolga EVP, Chief Commercial Officer
Sold at will 8×
$123.98K 513 at 241.68
3.5%
Not planned
28 Feb 2025
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold at will 8×
$119.88K 496 at 241.69
3.9%
Not planned
18 Feb 2025
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold on a plan 6×
$389.58K 1,548 at 251.67
11.4%
Planned (10b5-1)
18 Feb 2025
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 5×
$362.24K 1,440 at 251.56
10.1%
Planned (10b5-1)
14 Feb 2025
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold on a plan 12×
$398.32K 1,561 at 255.17
10.3%
Planned (10b5-1)
14 Feb 2025
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 12×
$169.20K 663 at 255.21
4.4%
Planned (10b5-1)
27 Jan 2025
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold on a plan
$14.99M 52,592 at 285.00
81.4%
Sold half or more
12 Dec 2024
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold on a plan 7×
$439.76K 1,752 at 251.00
10.0%
Planned (10b5-1)
27 Nov 2024
Fitzgerald Kevin Joseph CSO & EVP, Head of Research
Sold on a plan 4×
$386.26K 1,531 at 252.29
10.6%
Planned (10b5-1)
26 Nov 2024
Garg Pushkal CMO & EVP Dev & Med Affairs
Sold at will 5×
$422.14K 1,682 at 250.98
8.8%
Not planned
Showing 1–50 of 131. Page 1 of 3 Older →